Enavate Sciences GP, LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$279.8M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Enavate Sciences GP, LLC reported 8 positions worth $279.8M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ZBIO (28.1%). Biggest move: new buy BRVE ($74.2M).

8 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ZBIOZenas BioPharma$78.7M28.14%2,919,159———
▸ 2 IMNMImmunome$77.7M27.79%3,613,799——-12.7%
▸ 3 BRVEBraveheart Bio$74.2M26.53%3,674,656——-2.9%
▸ 4 SIONSionna Therapeutics$13.0M4.66%2,478,030——-36.7%
▸ 5 UPBUpstream Bio$13.0M4.63%2,459,703——-47.2%
▸ 6 BBOTBridgeBio Oncology Therapeutics$10.8M3.85%2,626,946——-47.8%
▸ 7 CMPXCompass Therapeutics$8.1M2.90%7,788,150——-25.6%
▸ 8 CAMPCamp4 Therapeutics$4.2M1.50%1,041,127——-5.9%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Enavate Sciences GP, LLC hold as of Q3 2026?

Enavate Sciences GP, LLC reported 8 positions worth $279.8M in its Q3 2026 13F filing. Largest positions: ZBIO (28.1%), IMNM (27.8%), BRVE (26.5%), SION (4.7%) and UPB (4.6%).

What did Enavate Sciences GP, LLC buy in Q3 2026?

New positions: BRVE.

What did Enavate Sciences GP, LLC sell in Q3 2026?

Reduced: ZBIO and CAMP.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.